FATE — Fate Therapeutics, Inc.

FATEFate Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · fatetherapeutics.com

2.145USD-4.67%Mkt Cap: 252.92M USDP/E: —Last update: 2026-05-26

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen r…

Industry Peers

Biotechnology

VRTX

Vertex Pharmaceuticals Incorporated

Regeneron Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

39.41BUSDP/E 74.0

RVMD

Revolution Medicines, Inc.

Indicators:|

Key Statistics

Company

Market Cap252.92M USD

Enterprise Value146.74M USD

Revenue (TTM)6.32M USD

Gross Profit-81.15M USD

Net Income (TTM)-136.31M USD

Revenue/Share0.0530 USD

Last Price2.145 USD

Fiscal Year EndDec 2025

MR QuarterMar 2026

Employees161

CountryUS

SectorHealthcare

IndustryBiotechnology

ISINUS31189P1021

Valuation

P/E (Trailing)—

P/E (Forward)-2.28

PEG—

EV/EBITDA-1.17

EV/Revenue23.23

P/S38.75

P/B1.36

EPS (TTM)-1.09

EPS (Forward)-0.92

52W Range

0.910079% of range2.470

52W High2.470 USD

52W Low0.9100 USD

Profitability

Gross Margin0.00%

Oper. Margin-2540.42%

EBITDA Margin0.00%

Profit Margin-2051.08%

ROE-65.79%

ROA-42.74%

Growth

Revenue Growth-20.30%

Earnings Growth—

Cash Flow & Leverage

Operating CF-106.08M USD

CapEx (TTM)5.95M USD

FCF Margin-792.72%

FCF Yield-19.80%

Net Debt-98.04M USD

Net Debt/EBITDA0.78

Balance Sheet

Debt/Equity0.38

Current Ratio5.85

Quick Ratio5.75

Book Value/Sh1.546 USD

Cash/Share1.500 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating2.1 (Buy)

Target (Mean)5.389 USD

Target Range2.000 USD – 8.000 USD

# Analysts9

Ownership

Shares Out.116.56M

Float102.46M

Insiders1.21%

Institutions80.13%

Short Interest

Short Ratio8.9d

Short % Float10.00%

Short % Out.8.82%

Shares Short10.26M

Short (prev mo.)9.86M

Technical

SMA 501.475 (+45.4%)

SMA 2001.245 (+72.3%)

Beta2.14

S&P 52W Chg28.31%

Avg Vol (30d)3.18M

Avg Vol (10d)3.58M

Technical Indicators

RSI (14)—

MACD—

MACD Signal—

MACD Hist.—

BB Upper—

BB Middle—

BB Lower—

BB Width—

ATR (14)—

Vol Ratio (20d)—